Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma
Authors:
- Yuchan LiYLYuchan Li
- Omar ElakadOEOmar Elakad
- Sha YaoSYSha Yao
- Alexander von Hammerstein-EquordAHAlexander von Hammerstein-Equord
- Marc HinterthanerMHMarc Hinterthaner
- Bernhard C. DannerBDBernhard C. Danner
- Carmelo FerraiCarmelo Ferrai
- Philipp StröbelPSPhilipp Ströbel
- Stefan KüfferSKStefan Küffer
- Hanibal BohnenbergerHBHanibal Bohnenberger
Open Access
- 15 July 2022
- journal article
- research article
- Published by MDPI AG in Metabolites
- Vol. 12 (7) , 652
Abstract
Activating KRAS mutations occur in about 30% of pulmonary adenocarcinoma (AC) cases and the discovery of specific inhibitors of G12C-mutated KRAS has considerably improved the prognosis for a subgroup of about 14% of non-small cell lung cancer (NSCLC) patients. However, even in patients with a KRAS G12C mutation, the overall response rate only reaches about 40% and mutations other than G12C still cannot be targeted. Despite the fact that one-carbon metabolism (1CM) and epigenetic regulation are known to be dysregulated by aberrant KRAS activity, we still lack evidence that co-treatment with drugs that regulate these factors might ameliorate response rates and patient prognosis. In this study, we show a direct dependency of Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) and Enhancer of Zeste Homolog 2 (EZH2) expression on mutationally activated KRAS and their prognostic relevance in KRAS-mutated AC. We show that aberrant KRAS activity generates a vulnerability of AC cancer cell lines to both MTHFD2 and EZH2 inhibitors. Importantly, co-inhibition of both factors was synergistically effective and comparable to KRASG12C inhibition alone, paving the way for their use in a therapeutic approach for NSCLC cancer patients.Keywords
Funding Information
- Deutsche Krebshilfe Foundation (70112551, KFO5002)
- University Medical Center Göttingen (70112551, KFO5002)
- Else-Kröner-Fresenius-Foundation (70112551, KFO5002)
- chinese scholarship counsil (70112551, KFO5002)
- DFG (70112551, KFO5002)
This publication has 56 references indexed in Scilit:
- Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancerNature Communications, 2014
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2Proceedings of the National Academy of Sciences, 2013
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutationsNature, 2012
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose MetabolismCell, 2012
- Intracellular ATP Levels Are a Pivotal Determinant of Chemoresistance in Colon Cancer CellsCancer Research, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Clues from cell metabolismNature, 2010
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay MethodCancer Research, 2010
- Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell lineProceedings of the National Academy of Sciences, 2008